Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study

Verfasser / Beitragende:
[K.L. Blackwell, K. Zaman, S. Qin, KHR Tkaczuk, M. Campone, D. Hunt, R. Bryce, L.J. Goldstein]
Ort, Verlag, Jahr:
2019
Enthalten in:
Clinical breast cancer, 19/2(2019-04), 97-104.e4
Format:
Artikel (online)
ID: 563230606